Niuhuang Jiedu tablets, anti-viral oral liquid and other drugs were inspected
On June 12, the Zhejiang Provincial Food and Drug Administration issued the first phase of the 2020 Zhejiang Province Drug Quality Inspection and Announcement (hereinafter referred to as "announcement").
The announcement pointed out that the bureau has recently organized and carried out random sampling inspections of the relevant drug quality of the drug production, operation and use units within its jurisdiction. During the inspection, it was found that 48 batches of drugs did not comply with the regulations.
Among them, 8 batches are preparations and 40 batches are decoction pieces. Among the 48 batches of drugs, Kudiezi injection produced by Shenyang Shuangding Pharmaceutical Co., Ltd. and Fabanxia produced by Anhui Xiehecheng Pharmaceutical Pieces Co., Ltd. all had re-inspection results in compliance with the regulations. This also means that the product quality problem is not a production quality problem of the production enterprise, and the quality problem may appear in other links such as circulation, transportation or storage.
In addition, it should be noted that there are many commonly used drugs in these 48 batches of drugs, including Yupingfeng oral liquid, Niuhuang Jiedu tablets, antiviral oral liquid, compound paracetamol tablets, Guizhi Fuling pills, Banlangen, honeysuckle...
For the above unqualified drugs, the bureau requires that, based on the measures that have been taken, all localities should further check and dispose of drugs and related units that do not meet the standards, effectively eliminate hidden dangers, and ensure the quality and safety of drugs.
2026-10-20
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
China’s 15th Five-Year Plan Sets New Priorities for Pharmaceutical Innovation and Supply Chains
-
Evonik Expands Slovakian Fermas Site with €80 Million Investment to Boost Pharmaceutical CDMO Capacity
-
India's PV Community Comes Together at the 6th Edition Drug Safety Symposium 2026 – India Chapter to Shape the Future of Patient Safety
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
Trump Plans 25% Tariffs on Autos, Drugs and Semiconductor Chips
-
ECHEMI平台投诉处罚规则 - ECHEMI platform complaint penalty rules
-
The project of fine chemicals with 4000 t/a Tebuconazole and Diflufenican is to be built
-
Ministry of Industry and InformationTechnology: 14 initiatives to help SMEs digital transformation
-
Jiangsu: Special graphite new material production project landed in Suyin Industrial Park
-
Guide to digital transformation of smalland medium-sized enterprises issued
Recommend Reading
-
China’s New Food-Contact Standards Take Effect, Resetting Compliance for Coatings and Silicone Rubber
-
U.S. Formally Publishes India PFA Trade Cases, Raising New Barriers for Fluoropolymer Supply
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
关于进一步规范化学品信息发布、加强全球管制目录宣导的公告 Announcement on Further Standardizing the Release of Chemical Information and Strengthening Public Awareness of Global Control Lists
-
EU Chemicals Regulatory Update: Practical Compliance Actions Following ECHA January 2026 Developments
-
Escalating Conflict Drives Up Risk Premium; Crude Oil Hits New High in Over a Month
-
Cost support weakens, sodium metabisulfite prices fall
-
Business Society’s Urea Market Outlook on September 4, 2026: Volatile
-
This Week's Aniline Market Shows High Prices (8.31-9.4) in China
-
Business Society’s Market Outlook for n-Butanol on September 4, 2026: Fluctuating Trend